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simvastatin and bone marrow-derived








Objectives: We postulated that combining high-dose simvastatin with bone marrow derived-mesenchymal stem
cells (MSCs) delivery may give better prognosis in a mouse hindlimb ischemia model.
Methods: Mouse hindlimb ischemia model was established by ligating the right femoral artery. Animals were
grouped (n = 10) to receive local injection of saline without cells (control and simvastatin groups) or with 5 × 10
6
MSCs (MSCs group).Animals received either simvastatin (20 mg/kg/d, simvastatin and combination groups) or saline
(control and MSCs group) gavages for continual 21 days. The blood flow was assessed by laser Doppler imaging at
day 0,10 and 21 after surgery, respectively. Ischemic muscle was harvested for immunohistological assessments and
for VEGF protein detection using western blot assay at 21 days post-surgery. In vitro, MSCs viability was measured
by MTT and flow cytometry following culture in serum-free medium for 24 h with or without simvastatin. Release
of VEGF by MSCs incubated with different doses of simvastatin was assayed using ELISA.
Results: Combined treatment with simvastatin and MSCs induced a significant improvement in blood reperfusion,
a notable increase in capillary density, a highest level of VEGF protein and a significant decrease in muscle cell
apoptosis compared with other groups. In vitro, simvastatin inhibited MSCs apoptosis and increased VEGF release
by MSCs.
Conclusions: Combination therapy with high-dose simvastatin and bone marrow-derived MSCs would augment
functional neovascularization in a mouse model of hindlimb ischemia.
Introduction
Peripheral arterial disease (PAD) is one of the most com-
mon clinical manifestations of atherosclerosis, which
affects a significant number of individuals. It represents
an important cause of disability and is associated with
elevated cardiovascular morbidity and mortality[1].
Treatment of PAD includes anticoagulants and antiplate-
let drugs, percutaneous transluminal angioplasty, and
bypass surgery. However, the prognosis for patients with
PAD still remains poor, and amputation of the lower
extremities is often required [2]. Several types of stem
cells have been used for therapeutic neovascularization,
including the bone marrow-derived mesenchymal stem
cells (MSCs), which have attracted a great attention from
investigators because of their plasticity and availability[3].
These cells mediate their therapeutic effects by homing
to and integrating into injured tissues, differentiating into
endothelial cells, and/or producing paracrine growth fac-
tors. However, recent studies have shown that patients
with PAD are often coincident with cardiovascular risk
factors, such as aging, diabetes mellitus, which reduce the
availability of progenitor cells and impair their function
to varying degrees[4-6], likely limiting the efficiency of
stem cell therapy. Therefore, optimization of strategies to
improve the therapeutic potential of cell therapy needs to
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for patients with cardiovascular diseases.
Statins are 3-hydroxy-3-methyl-glutaryl-CoA reductase
inhibitors and are primarily used to lower circulating
cholesterol levels. In addition, studies have revealed sta-
tin’s pleiotropic effects, such as the protection of
endothelial function, increased nitric oxide bioavailabil-
ity, antioxidant effects, anti-inflammatory reaction, and
stabilization of atherosclerotic plaques[7,8]. Recent stu-
dies have demonstrated that statins could protect
against ischemic injury of the heart [9]and stimulate
angiogenesis in ischemic limbs of normocholesterolemic
animals [10]. However, both in vitro and in vivo studies
have suggested a biphasic and dose-dependent effect of
statins on angiogenesis [11]. Yang demonstrated that
low-dose simvastatin could enhance the therapeutic
effects of bone marrow cells in pig’s acute myocardial
infarction model [12]. Whereas, some studies indicated
that high-dose statins could also enhance angiogenesis
in vivo [13]. Accordingly, we investigated whether the
combination therapy with high-dose simvastatin admin-
istration and MSCs transplantation could augment func-




Adult male Sprague-Dawley rats (80-100 g) were pur-
chased from Slac company (Shanghai, China).Adult
female C57BL/6J mice (8 weeks, 20-25 g) were provided
by the Model Animal Research Center of Nanjing Uni-
versity (Nanjing, China). All animal experimental proto-
cols were approved by the Animal Care and Use
Committee of Nanjing Medical University and were in
compliance with Guidelines for the Care and Use of
Laboratory Animals, as published by the National Acad-
emy Press (NIH Publication No. 85-23, revised 1996)
Isolation, expansion and labeling of MSCs
Rat MSCs were isolated with a modified procedure as
described previously [14]. In brief, Sprague-Dawley rats
were sacrificed by cervical dislocation. Femora and tibia
were aseptically harvested. Whole marrow cells were
obtained by flushing the bone marrow cavity with low
glucose Dulbecco’s Modified Eagle’s Medium (L-DMEM,
Hyclone, USA). Cells were centrifuged at 1000 × g for
5 minutes and the supernatant was removed. The cell
pellet was then re-suspended with L-DMEM supplemen-
ted with 10% fetal bovine serum (FBS, Hyclone, USA),
100 U/ml penicillin (Gibco,USA), 100 U/ml streptomycin
(Gibco,USA), and incubated at 37°C in a 5% CO2 atmo-
sphere. After 24 hours, non-adherent cells in suspension
were discarded and culture media was changed every
three or four days thereafter. When MSCs reached
70%-80% of confluence, they were trypsinized by the
addition of 0.25% trypsin-EDTA (Sigma-Aldrich, USA),
and then re-plated in culture flasks. Cells between 3
rd
and 6
th passage were utilized for experiment.
Mouse Model of Unilateral Hindlimb Ischemia
Unilateral hindlimb ischemia was created in 8-week-old
female C57BL/6J mice as described previously [15,16].
Briefly, mice were anesthetized with pentobarbital
(50 mg/kg, intraperitoneally) and the right femoral
artery was dissected free along its entire length. All
branches were ligated and excised. The left hindlimb
was kept intact and used as the nonischemic limb.
Simvastatin administration and MSCs transplantation
Simvastatin administration and MSCs transplantation
were performed immediately after hindlimb ischemia
was created. Simvastatin (20 mg/kg per day) or vehicle
(saline) was administered every day by gavage for
21 days. MSCs (5 × 10
6 cells/50 μl per mouse) or 50 μl
saline was injected into the ischemic thigh muscle with
a2 6 - g a u g en e e d l ea tf i v ed i f f e r e n tp o i n t s .T h i sp r o t o c o l
resulted in the creation of four groups (n = 10/group):
(1) vehicle administration plus saline injection (control
group), (2) simvastatin administration plus saline injec-
tion (simvastatin group), (3) vehicle administration plus
MSCs transplantation (MSCs group), (4) simvastatin
administration plus MSCs transplantation (combination
group). Simvastatin was kindly donated by Merck & Co.,
Inc., USA. MSCs were labeled with 1,1’-dioctadecyl-
3,3,3’3’-testramethylindo-carbocyanine perchlorate (DiI)
before transplantation as described previously[17].
Briefly, 2 μg/ml DiI was added to cells suspension and
incubated at 37°C for 5 minutes, then at 4°C for 15 min-
utes with occasional mixing. MSCs labeled with DiI
were washed 3 times with PBS and then collected.
Laser Doppler blood perfusion analysis
The ratio of ischemic/normal hindlimb blood flow was
measured using laser Doppler blood perfusion imager
(PeriScan PIM 3, Swenden) as described previously
[15,16].Low to no flow was displayed as dark blue,
whereas high blood flow was displayed as red to white.
Previous study has demonstrated [16] that hindlimb
blood flow was progressively augmented over the course
of 14 days, ultimately reaching a plateau between 21
and 28 days in mouse hindlimb ischemia model. There-
fore, at three predetermined time points (immediately
after surgery, and on postoperative days 10 and 21), we
performed 2 consecutive laser scanning over the same
region of interest (legs and feet). The average flow of
the ischemic and nonischemic legs was calculated on
the basis of histograms of the colored pixels. To mini-
mize variations due to ambient light, blood flow was
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Histological assessment for capillary density
Ischemic limb muscles were harvested at day 21 after
treatment and embedded in optimal cutting temperature
compound. Frozen tissue sections of 5 μm-thick were
stained for alkaline phosphatase [18] to examine the
capillary density. To ensure that the capillary densities
were not overestimated as a consequence of myocyte
atrophy or underestimated because of interstitial edema,
the capillary/muscle fiber ratio was determined.
Terminal deoxynucleotidy1 transferase-mediated dUTP
nick end-labeling assay
The terminal deoxynucleotidy1 transferase-mediated
dUTP nick end-labeling (TUNEL) assay was performed
to determine apoptotic activity in hindlimb ischemic tis-
sues using an In Situ Cell Death Detection Kit (Roche,
Germany) according to the manufacturer’si n s t r u c t i o n s .
Cells in which the nucleus was stained brown were
defined as TUNEL-positive and the percentage of apop-
totic cells per total number of cells was determined by
two independent blinded investigators.
Western blot analysis for the expression of VEGF protein
in vivo
Lysates from hind limb muscle tissue homogenates har-
vested at day 21 post-surgery were used for Western
blot analysis as described previously[19].Protein was
analyzed using 10% sodium dodecyl sulphate-polyacryla-
mide gel electrophoresis (SDS-PAGE) and transferred to
nitrocellulose membranes (Bio-Rad).Membranes were
then incubated with primary antibodies including VEGF
(1:1000, Cell Signaling) and b-actin (1:5000, Sigma) at 4°
C overnight respectively.The membranes were then
incubated with peroxidase labeled secondary antibody
(1:1000, Santa Cruz, USA) at 37°C for 2 hours. Signals
were detected by enhanced chemiluminescence (Amer-
sham, USA). Densitometric analysis for the blots was
performed with NIH image software.
Effect of simvastatin on the cell viability of bone marrow-
derived MSCs in vitro
To examine whether simvastatin has anti-apoptotic
effect on bone marrow-derived MSCs under hypoxia
stress, cells viability was detected by MTT assay and
flow cytometry measurement, respectively. Cells (1 ×
10
4 cells) were cultured in serum-free medium for 24 h
with 0.01 μmol/L of simvastatin, 0.01 μmol/L of simvas-
tatin plus 50 n M of wortmannin (phosphatidylinositol
3-kinase, PI3-K, inhibitor), or blank control. Cell viabi-
lity was evaluated using the MTT assay (MTT, Sigma)
and flow cytometry (Becton Dickinson) according to the
manufacturer’s instructions.
Effect of simvastatin on the release of VEGF of bone
marrow-derived MSCs in vitro
To examine whether simvastatin enhance the release of
VEGF by bone marrow-derived MSCs, a total of 1 × 10
4
MSCs were plated in serum-free medium with different
doses of simvastatin (0, 0.001, 0.01, 0.1 and 1.0 μmol/L)
on 48-well plates. VEGF levels in conditioned medium
were measured with VEGF ELISA kits (R&D Systems)
24 h after treatment.
Statistical analysis
All values were expressed as mean ± SD. Student’s
unpaired t test was used to compare differences between
every two groups. Comparisons of parameters among
t h r e eo rf o u rg r o u p sw e r em a d eb yo n e - w a yA N O V A ,
followed by Scheffe’ multiple comparison test. Compari-
sons of the time course of the LDPI index were made
by 2-way ANOVA for repeated measures, followed by
Scheffe’ multiple comparison tests. A probability value
< 0.05 was considered statistically significant.
Results
Identification of bone marrow-derived MSCs
During the primary cell culture, the attached cells
stretched and took the shape of a typical spindle-shaped
fibroblast phenotype. These adherent cells could be
readily expanded in vitro by successive cycles of trypsi-
nization, seeding and culture every 3 days for 15 pas-
sages without visible morphologic change. Flow
cytometry examination showed that these cells were
negative for CD34 and CD45, but positive for CD44 and
CD29 (Fig. 1). Thus, we designated these fibroblasts-like
cell populations as MSCs.
Combination therapy increases blood perfusion
To determine whether simvastatin or MSCs treatment
could stimulate the blood reperfusion in ischemic limb,
mice were treated with simvastatin or MSCs or vehicle,
the blood reperfusion was examined at day 0, 10 and 21
after the treatment by LDPI. LDPI showed that blood
flow in the ischemic hindlimb was decreased equally in
all four groups immediately after surgery. Over the sub-
sequent 21 days, blood perfusion of the ischemic hin-
dlimb notably improved in the treatment groups
(Fig. 2A) The laser Doppler perfusion index was signifi-
cantly higher in the simvastatin group, the MSCs group
and the combination group than in the control group
on day 10 after treatment and showed further improve-
ment afterwards on day 21. The LDPI index was the
highest in the combination group among the four
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Page 3 of 10Figure 1 Characterization of bone marrow-derived MSCs. Flow cytometric analyses of bone marrow-derived MSCs. Cells were uniformly
negative for CD34, CD45, and positive for CD44, and CD29.
Figure 2 Effect of simvastatin and bone marrow-derived MSCs administration on the blood reperfusion in ischemic limb. A.I nc o l o r -
coded images, normal perfusion is displayed as red, while low or absent perfusion is displayed as dark blue. Isch = Ischemic limb.N-Isch = Non-
Ischemic limb. B. Quantitative evaluation of ischemic/normal leg blood perfusion ratio. Values are presented as means ± SD (n = 10). *p < 0.05
and **p < 0.01 versus control, #p < 0.05 versus simvastatin, § p < 0.05 versus MSCs.
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1.00 ± 0.03 in this study.
Combination therapy increases capillary density in the
ischemic tissues
To determine whether improved limb reperfusion by the
simvastatin treatment or MSCs transplantation was
linked with increased angiogenesis in vivo, the capillary/
muscle fiber ratio was assessed in the ischemic muscle
at 3 weeks after the surgery by histochemical staining
for alkaline phosphatase and image analysis (Fig. 3).The
number of capillaries in each muscle fiber increased in
the mice treated with either MSCs or simvastatin alone
in comparison with the control group (p < 0.05). The
combined administration of simvastatin and MSCs
resulted in the highest capillary density (p <0 . 0 5v s .a l l
other groups).
Combination therapy enhances the differention of MSCs
into endothelial cells in ischemic muscles
To determine whether improved limb reperfusion by
simvastatin and MSCs co-therapy was associated with
differentiation into endothelial cells, the number of
incorporated DiI-labeled MSCs (red labeling) into the
mouse microvascular was detected by fluorescent stain-
ing against vWF (green labeling) (Fig. 4). Histological
and quantitative analyses showed that the number of
incorporated MSCs was significantly greater in the com-
bination group relative to MSCs alone (p < 0.05).
Combination therapy decreases cell apoptosis in vivo
To determine whether improved limb reperfusion by the
simvastatin/MSCs treatment was associated with
increased ischemic muscle cells survival in vivo, the cell
apoptosis was assessed in the ischemic muscle at days
21 after the treatment by TUNEL assay. Apoptosis as
measured by TUNEL positive nuclei (Fig. 5) was signifi-
cantly decreased in ischemic muscle of simvastatin and
MSCs treated mice versus vehicle-treated mice. The co-
treatment of simvastatin and MSCs resulted in a further
decrease of cell apoptosis.
Combination therapy enhances the expression of VEGF
protein in ischemic tissue
To examine whether high-dose simvastatin and MSCs
co-therapy improved postischemic neovascularization,
the expression of VEGF protein was detected by western
blot assay. As can be seen in figure 6, the expression of
VEGF significantly increased in the simvastatin group
than in the control group (p < 0.05). Moreover, the
expression of VEGF was higher in MSCs group com-
pared with that in the simvastatin group, but was lower
than that in the combination group (p < 0.05).
Effect of simvastatin on the cell viability of bone marrow
-derived MSCs in vitro
In vitro, serum starvation induced bone marrow-derived
MSCs apoptosis, as indicated by flow cytometry and MTT
assay. When incubated with 0.01 μmol/L of simvastatin,
the percentage of apoptotic cells decreased and the viabi-
lity was visibly upregulated. However, pretreatment with
50 n M wortmannin, a PI3-K inhibitor, diminished the
anti-apoptotic effect of simvastatin (Fig. 7). The cell viabi-
lity detected by MTT assay was significantly higher in sim-
vastatin treated group than that in the control group.
Although the cell viabilities were higher in simvastatin +
Figure 3 Effect of simvastatin and bone marrow-derived MSCs administration on angiogenesis in ischemic limb. A.R e p r e s e n t a t i v e
microphotographs of the section of ischemic hindlimb muscles stained histochemically for alkaline phosphatase, magnification × 400. B.
Quantitative analysis of capillary density in ischemic hindlimb muscles. Data are presented as mean ± SD (n = 10). * p < 0.05 and** p < 0.01
versus control. # p < 0.05 versus simvastatin. § p < 0.05 versus MSCs.
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was no significant difference between the two groups.
These results indicated that PI3-K pathway was of impor-
tance for the anti-apoptotic role of simvastatin.
Effect of simvastatin on the VEGF releasing of bone
marrow -derived MSCs in vitro
To assess whether simvastatin affected the release of
VEGF by MSCs, cells were cultured in the absence or
presence of various concentration of simvastatin for 24 h
and VEGF levels were measured in the conditioned med-
ium using ELISA. Results found that VEGF levels were
increased significantly in simvastatin-treated MSC cultures
with a maximal effect at 0.01 μmol/L (78.1 ± 5.4 pg/ml)
compared to control cultures (38.6 ± 2.2 pg/ml, p < 0.05).
The VEGF levels were reduced in 0.1 and 1.0 μmol/L sim-
vastatin-treated MSCs cultures when compared with 0.01
μmol/L simvastatin-treated cultures (Fig. 8).
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Figure 4 Effect of simvastatin on differentiation into endothelial cell of MSCs in ischemic limb. A. Representative microphotographs of
the section of ischemic hindlimb muscles stained with DiI and immunofluorescence for vWF. Red fluorescence (DiI)-labeled MSCs were
transplanted into ischemic thigh muscle and positive of vWF (white arrows indicated). B. Quantitative data for the number of DiI/vWF double-
positive cells.*p < 0.05 versus MSCs.
Figure 5 Effect of simvastatin and bone marrow-derived MSCs on the muscle cells apoptosis in ischemic limb. A.R e p r e s e n t a t i v e
microphotographs of the section of ischemic hindlimb muscles stained immunochemically for TUNEL (brown yellow), magnification × 400. B.
Quantitative analysis of apoptosis cells in ischemic hindlimb muscles. Data are presented as mean ± SD (n = 10). * p < 0.05 and ** p < 0.01
versus control. #p < 0.05 versus simvastatin, § p < 0.05 versus MSCs.
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The present study was designed to examine whether
high-dose simvastatin could enhance the therapeutic
effects of bone marrow-derived stem cells in the treat-
ment of ischemic hindlimb. Overall, this study demon-
strates more pronounced angiogenic response, decreased
muscle cell apoptosis and improved blood reperfusion
of ischemic muscle following combined therapy of high-
dose simvastatin and bone marrow-derived MSCs.
Bone marrow-derived MSCs have been identified as a
potential new therapeutic option to induce therapeutic
angiogenesis. The main advantage of using bone mar-
row-derived MSCs in treating ischemic disease is that
they can be isolated from bone marrow by aspiration
and expanded ex vivo before implantation. Under spe-
cialized culture conditions, bone marrow-derived MSCs
have the capacity to differentiate into cells such as bone,
cartilage, adipocytes and endothelial cells [5,20,21].
Figure 6 Effect of simvastatin and bone marrow-derived MSCs on the expression of VEGF in ischemic limb. The levels of VEGF in
ischemic limb 21 days after surgery is measured by Western blot. b-actin was used as an invariant control. *p < 0.05 and **p < 0.01 versus
control. #p < 0.05 versus simvastatin. &p < 0.05 versus MSCs.
Figure 7 Effect of simvastatin on the serum-free induced cell viability of bone marrow -derived MSCs in vitro. Cells were incubated with
vehicle or simvastatin plus wortmannin (W), a PI3-K inhibitor, or simvastatin alone for 24 h prior to viability assessment. Wortmannin was added
0.5 h prior to simvastatin. A. Histographic representation of nuclear DNA contents measured by flow cytometry. AP = Apoptotic cells. B. The
percentage of apoptotic MSCs analyzed by flow cytometry. C. Cell viability analyzed by MTT. Means ± SD. n = 6 wells per group. The data are
representative of 3 individual experiments. * p < 0.05 versus control group. # p < 0.05 versus simvastatin + W group.
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may be good candidates for cell transplantation. How-
ever, some patients are refractory to this cell therapy.
Patients with PAD often accompany with several cardio-
vascular risk factors, such as aging, smoking, diabetes
mellitus, et al, which impair the stem cell functions to
varying degrees, likely limiting the efficiency of stem cell
therapy. Therefore an approach to augment the angio-
genic potency of bone marrow-derived MSCs transplan-
tation is of great importance.
Statins, also known as the 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors, are the first-line
agents used in hypercholesterolemia[19]. They are also
characterized by having other benefits apart from their
lipid-lowering effects[22]. Among these pleiotropic
effects are the anti-apoptotic and pro-angiogenic proper-
ties of statins. It has been demonstrated that statins
could protect against ischemic injury of the heart and
stimulate angiogenesis in ischemic limbs of normocho-
lesterolemic animals. In the present study, we demon-
strated that combination of MSCs transplantation and
high-dose simvastatin treatment provided advanced ben-
efits on treatment for hindlimb ischemic, compared with
either treatment alone.
Combination treatment significantly enhanced capil-
lary density in ischemic limbs than cell therapy alone.
This may be partially due to the enhanced stem cells
survival and greater differentiation rate of MSCs into
vascular cells when administrated with simvastatin
simultaneously. In vitro, a higher cell proliferation and
decreased apoptosis under serum-free culture was
demonstrated after bone marrow-derived MSCs incu-
bated with simvastatin by MTT assay and flow cytome-
try measurement, respectively. An earlier study has
demonstrated that ischemia and mechanical stress
induce apoptosis of transplanted bone marrow cells
[23]. In this in vitro study, we revealed that simvastatin
inhibited serum starvation-induced MSC apoptosis,
which may partly be blocked by wortmannin, a PI3-K
inhibitor, indicating that the PI-3K/Akt pathway may be
an important way in the regulation of MSCs apoptosis.
Enhanced expression of angiogenic growth factors in
the ischemic tissue is another contributor to augment
angiogenesis resulting from combinatorial treatment. It
is well known [24-26] that bone marrow-derived MSCs
could paracrine several angiogenic growth factors such
as VEGF, etc. On the other hand, recent studies have
demonstrated that statins strongly induced angiogenesis
with increases in angiogenic cytokines [27,23]. In vitro,
a higher expression of VEGF was detected in bone mar-
row-derived MSCs culture medium compared with
blank control, indicating that MSCs could release a
mount of angiogenic growth factors in hypoxic environ-
ment. Simultaneously, a highest expression of VEGF
protein was detected in combination group in vivo.
However, the release of VEGF by MSCs was reduced
when the concentration of simvastatin increased in
vitro. This indicated that the simvastatin has a biphasic
dose-dependent effect on angiogenesis in vitro. Weis et
al previously demonstrated that statins have proangio-
genic effects at low therapeutic concentrations (0.5 mg/
kg/d of cerivastatin) but angiostatic effects at high con-
centrations (2.5 mg/kg/d) in apolipoprotein E-deficient
hypercholesterolemic C57BL/6J mice. In the present
study, simvastatin augmented angiogenesis in response
to acute ischemia at even a higher dose (20 mg/kg/d).
Masataka Sata has previously demonstrated [13] that
high-dose statins (5 mg/kg/d cerivastatin) promoted
blood flow recovery in the ischemic hind limb as deter-
mined by LDPI. In a stroke model in mice, atorvastatin
(10 mg/kg/d) administered subcutaneously after stroke
for 14 days brought about an improvement in neurolo-
gic recovery, which was related with an increase in
VEGF, VEGF receptor 2, brain-derived neurotrophic fac-
tor, and endothelial cell proliferation in the ischemic
territory [28]. A recent study revealed [29] that the
same dose of simvastatin promoted angiogenesis in
response to hypoxic conditions, but decreased angiogen-
esis mediated by inflammation. Therefore, it might be
plausible that proangiogenic or antiangiogenic effects of
statins might depend on distinct mechanisms of angio-
genesis associated with inflammation, hypoxia, tissue
ischemia, or cancer.
Promotion of limb muscle cells survival under hypoxic
circumstance might be another contributor to improved
blood reperfusion of ischemic muscle following com-
bined therapy of simvastatin and bone marrow-derived
MSCs. Apoptosis is defined as a programmed cell death
or cell suicide, which determines the lifespan and coor-
dinates the removal of cells. A line of evidence has been
demonstrated[30,31]that simvastatin and bone marrow-
derived MSCs both have the anti-apoptotic effects.
Franke C has demonstrated [30] that simvastatin could
Figure 8 Effect of simvastatin on the release of VEGF by bone
marrow-derived MSCs in vitro. MSCs were exposed to increasing
doses of simvastatin for 24 h. Then, 24 h after replacement of the
culture medium, VEGF concentration was measured by ELISA. Means
± SD of measurements from one experiment (n = 4). * p < 0.05
versus untreated controls.
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vival. Kortesidis and colleagues also demonstrated[31]
that bone marrow derived-MSCs express factors that
support cell survival and avoid apoptosis thereby preser-
ving cells which would otherwise be destroyed. As indi-
cated by TUNEL assay (Fig. 5), hindlimb muscle cells
underwent severe ischemic apoptosis after artery occlu-
sion. However, the apoptosis cells in ischemic muscle
regions were significantly reduced after simvastatin and
bone marrow-derived MSCs combined treatment.
Therefore, our study clearly demonstrated that bone
marrow-derived MSCs in combination with high-dose
simvastatin may be more effective or beneficial during
the ischemic scenario than bone marrow-derived MSCs
alone.
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